Evidence map›Paper›PMID 42524378›Full record

ArticleInternational journal of biological sciences2026

HLA class I-specific nucleolin peptides induce therapeutic T cells in triple-negative breast cancer patients.

Suyanee Thongchot, Niphat Jirapongwattana, Thaweesak Chieochansin, Jaturawitt Prasopsiri, Wannasiri Chiraphapphaiboon, Piriya Luangwattananun, Thanyada Rungrotmongkol, Kamonpan Sanachai, Nitchakan Darai, Doonyapat Sa-Nguanraksa and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Suyanee ThongchotDepartment of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand.
Niphat JirapongwattanaDepartment of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand.
Thaweesak ChieochansinSiriraj Center of Research Excellence for Cancer Immunotherapy, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand.
Jaturawitt PrasopsiriDepartment of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand.
Wannasiri ChiraphapphaiboonSiriraj Center of Research Excellence for Cancer Immunotherapy, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand.
Piriya LuangwattananunSiriraj Center of Research Excellence for Cancer Immunotherapy, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand.
Thanyada RungrotmongkolCenter of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330 Thailand.
Kamonpan SanachaiDepartment of Biochemistry, Faculty of Science, Khon Kaen University, Khon Kaen 40002 Thailand.
Nitchakan DaraiFuturistic Science Research Center, School of Science, Walailak University, Nakhon Si Thammarat 80160 Thailand.
Doonyapat Sa-NguanraksaDivision of Head-Neck and Breast Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand.
Pornchai O-CharoenratBreast Center, MedPark Hospital, Bangkok 10110 Thailand.
Peti ThuwajitDepartment of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand.
Pa-Thai YenchitsomanusSiriraj Center of Research Excellence for Cancer Immunotherapy, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand.
Chanitra ThuwajitDepartment of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis and limited treatment options owing to the lack of expression of common therapeutic targets such as hormone receptors and HER2. Recent advances in immunopeptidomics have enabled the identification of tumor-associated antigen peptides that can elicit tumor-specific immune responses. We identified four novel HLA class I-restricted peptides derived from nucleolin (NCL), a protein overexpressed in TNBC that is associated with poor outcomes. We predicted and validated pNCL-01 through pNCL-04 because of its strong binding affinity to common HLA alleles (A*02:01 and B*15:01), with pNCL-04 demonstrating broad HLA-binding potential across 20 HLA alleles. Peripheral blood mononuclear cells (PBMCs) from both healthy donors and patients with TNBC were pulsed with these peptides, generating NCL-specific CD8

Indexed as

Histocompatibility Antigens Class IPeptidesPhosphoproteinsRNA-Binding ProteinsTriple Negative Breast NeoplasmsAntibodies, Monoclonal, HumanizedCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansMDA-MB-231 CellsNucleolinAntibodies, Monoclonal, HumanizedatezolizumabHistocompatibility Antigens Class INucleolinPeptidesPhosphoproteinsRNA-Binding ProteinsHLA class Iimmunotherapynucleolinshort peptidetriple-negative breast cancer

Identifiers

PMID42524378
PMCPMC13412292

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.